January 09, 2012
BioReliance Holdings, Inc., a leading provider of global biopharmaceutical testing services, announced today that it has reached agreement to be acquired by Sigma-Aldrich Corporation for $350 million. The all-cash transaction, which was approved by Avista Capital Partners, majority owner of BioReliance, is subject to customary closing conditions, including regulatory clearance, and is expected to close in the first quarter of 2012. Global law firm Weil, Gotshal & Manges was counsel to BioReliance on the transaction.
Based in Rockville, Maryland, BioReliance provides contract biologic and specialized toxicology testing services, as well as animal health services, to the pharmaceutical and biopharmaceutical industries. Sigma-Aldrich, headquartered in St. Louis, Missouri, specializes in biochemical and organic chemical products and kits used in scientific and genomic research, biotechnology, pharmaceutical development, disease diagnoses, and other high technology manufacturing.